Detalhe da pesquisa
1.
Untimely TGFß responses in COVID-19 limit antiviral functions of NK cells.
Nature
; 600(7888): 295-301, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34695836
2.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Lancet
; 403(10422): 147-159, 2024 Jan 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38008109
3.
Transcriptional licensing is required for Pyrin inflammasome activation in human macrophages and bypassed by mutations causing familial Mediterranean fever.
PLoS Biol
; 20(11): e3001351, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36342970
4.
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
J Allergy Clin Immunol
; 2024 Feb 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38431226
5.
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
Lancet
; 401(10375): 458-469, 2023 02 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36774155
6.
Serum TGF-ß as a predictive biomarker for severe disease and fatality of COVID-19.
Eur J Immunol
; 53(10): e2350433, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37386908
7.
Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases.
Allergy
; 79(1): 37-51, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37605867
8.
Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.
Allergy
; 79(1): 93-103, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37597162
9.
Targeting Histamine Receptor 4 in Cholinergic Urticaria with Izuforant (LEO 152020): Results from a Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Crossover trial.
Br J Dermatol
; 2024 Feb 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38308655
10.
A Novel Method for Total IgE Purification from Human Serum.
J Immunol
; 208(10): 2436-2442, 2022 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35523453
11.
Modelling of patient journey in chronic spontaneous urticaria: Increasing awareness and education by shorten patients' disease journey in Germany.
J Eur Acad Dermatol Venereol
; 2024 Mar 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38441370
12.
BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria.
J Allergy Clin Immunol
; 2023 Dec 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38141832
13.
The 7-day recall period version of the Urticaria Control Test-UCT7.
J Allergy Clin Immunol
; 152(5): 1210-1217.e14, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37210040
14.
Virus-infected mast cells activate virus-specific CD8+ T cells.
Scand J Immunol
; 98(2): e13272, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-38441354
15.
Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances.
Allergy
; 78(2): 389-401, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36448493
16.
Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases.
Allergy
; 78(12): 3118-3135, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37555488
17.
Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria.
Allergy
; 78(5): 1269-1279, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36385701
18.
UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan.
Allergy
; 78(10): 2581-2595, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37641384
19.
In Chronic Spontaneous Urticaria, Complete Response to Antihistamine Treatment Is Linked to Low Disease Activity.
Int Arch Allergy Immunol
; 184(5): 421-432, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36652936
20.
Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.
Br J Dermatol
; 189(5): 511-519, 2023 10 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37290787